Abstract 3428
Background
Activated NK-cells are known to play immune-regulatory “helper” functions, being able to recruit and activate “bystander” DCs and to promote cross-presentation of cell-associated antigens to CD8+ T cells by producing IFN-γ and TNF-α. We have recently shown that intratumoral administration of pro-inflammatory allogeneic mouse DCs (alloDCs) induce NK-cell recruitment and that human GMP-produced human alloDCs (ilixadencel) used in clinical trials (NCT00625755, NCT01974661, NCT02686944, NCT02432846), promote enhanced cytotoxicity and strong IFN-γ production in allogeneic NK-cells in vitro. Furthermore, co-culture of ilixadencel with allogeneic PBMCs leads to a pro-inflammatory environment inducing maturation and strongly enhanced cross-presentation in "bystander" DCs. Here we investigated the anti-tumor effect of intratumorally administered pro-inflammatory mouse alloDCs as monotherapy and in combination with anti-PD-1 or anti-CD137.
Methods
AlloDCs were produced from C57BL/6 mice and activated with a cocktail consisting of polyI:C, R848 and IFN-γ. After cryopreservation and subsequent thawing the cells were injected intratumorally 2 or 3 times starting at day 14 post subcutaneous CT-26 tumor cell inoculation in Balb/C mice. AlloDCs were given as monotherapy or in combination with anti-PD-1 or anti-CD137. The studies were conducted at Charles River Laboratories, Morrisville, NC, USA.
Results
AlloDCs did not significantly delay tumor progression, likewise did not anti-PD-1. Combined treatment with alloDCs/anti-PD-1 significantly delayed tumor progression, while treatment with intratumoral administrations of polyI:C combined with anti-PD-1 showed no significant delay. Anti-CD137 treatment significantly delayed tumor progression and also induced one complete (10%) tumor response. Notably, the combination of alloDCs with anti-CD137 induced a highly significant anti-tumor synergy, including complete tumor eradication in 3 out of 9 mice (33%).
Conclusions
Intratumoral administration of allogeneic pro-inflammatory DCs induces a synergistic anti-tumor response when combined with systemic anti-PD-1 or anti-CD137 treatment.
Clinical trial identification
Legal entity responsible for the study
Immunicum AB, Gothenburg, Sweden.
Funding
Immunicum AB, Gothenburg, Sweden.
Editorial Acknowledgement
Disclosure
A. Karlsson-Parra: Ownership of stocks in Immunicum AB; Employee: Immunicum. All other authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract